NCT04954534Unknown不适用
Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM® Phase-I/IIa Clinical Trial
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Change from the baseline in ADAS-Cog
研究概览
简要总结
This study is to evaluate of Exploratory Efficacy of NEUROSTEM® in Subjects who control group of NEUROSTEM® Phase-I/IIa Clinical Trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have been treated with placebo in phase 1/2a clinical trial of NEUROSTEM®
- •Subjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative)
排除标准
- •History of stroke within 3 months prior to study enrollment
- •Severe liver disorder (equivalent to double the normal values of ALT and AST) at Visit 1
- •Severe kidney disorder (serum creatinine ≥1.5mg/dL) at Visit 1
- •Abnormal Laboratory findings at Visit 1
- •Hemoglobin < 9.5 g/dL for male and <9.0 g/dL for female
- •Total WBC Count < 3000/mm3
- •Total Bilirubin >= 3 mg/dL
- •Suspected active lung disease based on chest X-ray at Visit 1
- •Bleeding disorder (abnormal blood coagulation test result (i.e. platelet count of < 137,000/mm3, PT ≥ 1.5 INR, or aPTT ≥ 1.5 x control anti-coagulant or anti-platelet, without anticoagulant or anti-platelet therapy)
- •Diagnosis of cancer (of any body system, including brain tumor)
- •Contraindicated for any of the tests performed during the clinical trial period (for example, MRI, CT, PET)
- •Whom the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above
结局指标
主要结局
Change from the baseline in ADAS-Cog
时间窗: 4weeks,8weeks,12weeks,24 weeks after the first dose
The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment.
次要结局
- Change in CDR-SOB(24 weeks after the first dose)
- Change from the baseline in CGA-NPI(24 weeks after the first dose)
- Change from the baseline in SIB(24 weeks after the first dose)
- Change in CIBIC-plus(24 weeks after the first dose)
- Change from the baseline in K-MMSE(korean version)(24 weeks after the first dose)
- ADAS-Cog Response Rate(The ADAS-cog response is defined as no worsening (no change or improvement on ADAS-cog score) of the ADAS-cog score at 24 weeks after the first administration compared to the baseline)
- Change from the baseline in CSF biomarkers(24 weeks after the first dose)
研究者
Duk Lyul Na
Principal Investigator
Samsung Medical Center
研究点 (2)
Loading locations...
相似试验
终止
不适用
Effects of Neuro-Stim System on Pain, Sleep, and Opioid UsePain (Visceral, Somatic, or Neuropathic)NCT02673684Defense and Veterans Center for Integrative Pain Management17
Unknown
不适用
The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADAlzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesDelirium, Dementia, Amnestic, Cognitive DisordersMental DisordersDementiaNCT01696591Duk Lyul Na14
已完成
不适用
Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain SyndromeMyofascial Pain SyndromeNCT02179320University of Sao Paulo General Hospital40
招募中
不适用
Exploratory study regarding the use of Neurophysiological Monitoring Techniques to Detect Spinal Cord Ischemia in Patients after Thoracoabdominal Aortic Aneurysm Repair10003184myelum ischemiaspinal cord damage1004154310002363NL-OMON52997Medisch Universitair Ziekenhuis Maastricht60
已完成
不适用
Non-invasive Neurostimulation in Parkinson's DiseaseParkinson's DiseaseNCT01615718Spaulding Rehabilitation Hospital48